


Pharmaceuticals & Biotechnology | Small Cap
Alembic Ltd, a real estate company, shows a mixed financial performance. The company demonstrates strong solvency and coverage ratios. Growth ratios are also robust, driven by significant increases in operating profit, EPS, asset, and net income. However, liquidity ratios are poor, indicating potential difficulties in meeting short-term obligations. Efficiency ratios are also low, suggesting ineffective asset utilization. While profitability metrics like ROCE and ROE are strong, others such as gross profit margin and operating margin are weak, resulting in an average profitability score. Financial ratios are also average due to moderate adjusted EPS, cash EPS, book value per share and dividend per share. Overall, Alembic Ltd exhibits strengths in long-term financial health and growth, but faces challenges in short-term liquidity and operational efficiency.
Alembic Ltd, a real estate company, shows a mixed financial performance. The company demonstrates strong solvency and coverage ratios. Growth ratios are also robust, driven by significant increases in operating profit, EPS, asset, and net income. However, liquidity ratios are poor, indicating potential difficulties in meeting short-term obligations. Efficiency ratios are also low, suggesting ineffective asset utilization. While profitability metrics like ROCE and ROE are strong, others such as gross profit margin and operating margin are weak, resulting in an average profitability score. Financial ratios are also average due to moderate adjusted EPS, cash EPS, book value per share and dividend per share. Overall, Alembic Ltd exhibits strengths in long-term financial health and growth, but faces challenges in short-term liquidity and operational efficiency.
Overall Valuation Score
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
Today's Low: 0.00
Today's High: 0.00
P/E RATIO (TTM)
17.87
Industry Median
30.92
Small Cap Median
28.82
P/E RATIO
7.01
P/B RATIO
0.91
Industry Median
3.39
Small Cap Median
2.92
P/S RATIO
9.20
Industry Median
3.36
Small Cap Median
2.72
Others
PEG RATIO
-4.49
EV/EBITDA RATIO
13.57
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹86.66 as on Aug 6, 2026.
The company demonstrates robust growth, driven by strong increases in operating profit, EPS, asset base and net income. This growth trajectory indicates effective strategic initiatives and market positioning. While revenue growth is still low, the positive trends in profit and asset growth highlight the company's potential for sustained expansion. Continuing to capitalize on these growth drivers is essential for enhancing long-term shareholder value.
| Growth Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue Growth Rate | 5.41 | 62.82 | 23.62 | 41.4 | 8.11 |
| Operating Profit Growth Rate | 27.27 | 185.71 | 42.5 | 64.91 | -4.26 |
| Earnings Per Share (EPS) Growth | -35.21 | -14.22 | 40.97 | 15.68 | 2.15 |
| Asset Growth Rate | 9.26 | -16.22 | 5.62 | 7.47 | 3.48 |
| Net Income Growth Rate | -35.28 | -13.96 | 40.84 | 15.61 | 1.93 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | Jagsonpal Pharmaceuticals Ltd | 8.51 | 37.02 | Overvalued | 58.00 | 6.54 | 43.00 |
| 2 | Amrutanjan Health Care Ltd | 8.25 | 73.76 | Highly Overvalued | 31.00 | 20.03 | 21.00 |
| 3 | Windlas Biotech Ltd | 7.52 | 27.76 | Neutral | 105.00 | 32.19 | 66.00 |
| 4 | Lincoln Pharmaceuticals Ltd | 7.31 | 13.81 | Neutral | 98.00 | 43.88 | 88.00 |
| 5 | Aarti Drugs Ltd | 7.20 | 19.23 | Undervalued | 309.00 | 18.54 | 195.00 |
| 6 | RPG Life Sciences Ltd | 7.12 | 38.61 | Neutral | 147.00 | 69.64 | 115.00 |
| 7 | Morepen Laboratories Ltd | 7.12 | 45.91 | Neutral | 126.00 | 1.21 | 96.00 |
| 8 | Alembic Ltd | 7.06 | 7.01 | Undervalued | 90.00 | 4.85 | 317.00 |
| 9 | Syncom Formulations (India) Ltd | 6.92 | 16.27 | Undervalued | 77.00 | 0.81 | 76.00 |
| 10 | Hester Biosciences Ltd | 6.54 | 37.59 | Neutral | 87.00 | 61.24 | 57.00 |
| 11 | Sigachi Industries Ltd | 6.49 | 11.55 | Highly Undervalued | 54.00 | -2.08 | -83.00 |
| 12 | SMS Pharmaceuticals Ltd | 5.94 | 32.80 | Neutral | 171.00 | 9.35 | 102.00 |
| 13 | Gufic BioSciences Ltd | 5.49 | 63.18 | Neutral | 151.00 | 6.30 | 64.00 |
| 14 | Dishman Carbogen Amcis Ltd | 5.38 | 31.30 | Neutral | 566.00 | -2.45 | 97.00 |
| 15 | IOL Chemicals & Pharmaceuticals Ltd | 5.31 | 34.79 | Undervalued | 269.00 | 4.69 | 138.00 |
| 16 | Indoco Remedies Ltd | 5.26 | -21.52 | Neutral | 142.00 | -0.61 | -99.00 |
| 17 | Solara Active Pharma Sciences Ltd | 4.34 | -249.32 | Neutral | 187.00 | -1.50 | -7.00 |
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 1 Hour Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bearish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral